Letter: a Randomised Clinical Trial Comparing the Effects of Pregabalin with Those of Placebo on Functional Dyspepsia

Peng Chen,Fuchao Chen,Jiexin Lei,Yue Wu,Benhong Zhou

DOI: https://doi.org/10.1111/apt.16650

2021-01-01

Abstract:Editors, Kotikula et al1 conducted a randomised, doubleblind, placebocontrolled trial to evaluate the efficacy and safety of pregabalin among patients with functional dyspepsia (FD). Pregabalin significantly alleviated dyspeptic symptoms, especially among patients with predominant epigastric pain. Although this provided valuable information for the treatment of FD, we have some concerns. First, the effect of pregabalin on fundic accommodation and gastric emptying cannot be ignored. The symptoms of FD are not limited to pain; many patients with FD experience postprandial distress, forming the basis of the postprandial distress syndrome subtype of FD.2 An important driver of the onset of mealrelated symptoms may be impaired relaxation of the gastric fundus; medications including acotiamide, buspirone and sumatriptan are all thought to play a role in fundic relaxation.3 Delayed gastric emptying may also play a role in postprandial distress syndrome. The effects of pregabalin on fundic accommodation and gastric emptying are unknown from the current study. Second, the association of psychological factors with FD was not analysed. Psychological factors play a prominent role in the pathogenesis of FD, with anxiety, depression and neuroticism frequently reported as comorbidities.2 Some patients with comorbid anxiety and dyspeptic symptoms may benefit from the anxiolytic effects of pregabalin.4,5 Limited evidence suggests that pregabalin could be useful when administered as adjunctive therapy to patients with panic disorder, posttraumatic stress disorder or obsessivecompulsive disorder.6,7 In patients with comorbid anxiety or depression, the addition of pregabalin may have improved their dyspeptic symptoms by modulating their anxiety and improving anxietymediated, maladaptive responses to physiological stressors. However, the authors did not systematically measure anxiety before and after treatment to evaluate whether it was a factor associated with improvement in this study. Patients with FD may report more somatic symptoms than controls, which can lead to overreporting of medicationrelated side effects and lack of adherence to prescribed regimens.8 The ability to garner therapeutic confidence by the ‘low and slow’ approach to medication titration could significantly impact the success of treatments in this population. A liquid formulation of pregabalin may allow for more individualised and gentle dosing schedules.